Stem Cell-Based Toxicity Screening

@article{Greenhough2012StemCT,
  title={Stem Cell-Based Toxicity Screening},
  author={S. Greenhough and D. Hay},
  journal={Pharmaceutical Medicine},
  year={2012},
  volume={26},
  pages={85-89}
}
Preclinical cell-based toxicity screening is an essential stage in the drug development process. Current technology is based on immortalized cell lines, rodent cells and primary human hepatocytes, all of which suffer from shortcomings. Cell lines and rodent cells have limited relevance to human physiology, while primary human cells remain a scarce and variable resource. These systems are inadequate, as evidenced by the high levels of compound attrition in the clinical trial and postmarketing… Expand
Pluripotent stem cell-derived hepatocytes: potential and challenges in pharmacology.
Rules relating hepatotoxicity with structural attributes of drugs

References

SHOWING 1-10 OF 53 REFERENCES
Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism.
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes.
Highly efficient generation of human hepatocyte–like cells from induced pluripotent stem cells
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.
Disease-Specific Induced Pluripotent Stem Cells
In vitro evaluation of potential hepatotoxicity induced by drugs.
...
1
2
3
4
5
...